Canada Markets close in 3 mins

TFF Pharmaceuticals, Inc. (0K3.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.8250-0.0050 (-0.60%)
As of 09:15AM CET. Market open.
Full screen
Previous Close0.8300
Open0.8250
Bid0.8400 x N/A
Ask0.8700 x N/A
Day's Range0.8250 - 0.8250
52 Week Range0.7550 - 6.5000
Volume400
Avg. Volume11
Market Cap20.932M
Beta (5Y Monthly)1.74
PE Ratio (TTM)N/A
EPS (TTM)-0.7540
Earnings DateMar 22, 2023 - Mar 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
  • GlobeNewswire

    TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer

    FORT WORTH, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced the appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer. Dr. Mikhak will be responsible for the clinical development of the Company’s pipeline candidates, including the Inhaled Voriconazole Powder and Inhaled

  • GlobeNewswire

    TFF Pharmaceuticals Announces Leadership Transition

    Glenn Mattes to step down as Chief Executive Officer and as a Member of the Board of Directors Dr. Harlan F. Weisman, Vice Chairman of the Board, appointed as Interim Chief Executive Officer FORT WORTH, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that Glenn Mattes will ste

  • GlobeNewswire

    TFF Pharmaceuticals Announces Closing of $12.3 Million Public Offering

    Underwriters Exercise Their Option in FullFORT WORTH, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the closing of its previously announced underwritten offering of 10,675,001 shares of its common stock and warrants to purchase up to 5,337,501 shares of common stock. T